Arcellx, Inc. - Common Stock (NQ: ACLX )

100.14 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Where Arcellx Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2023
Via Benzinga
What 5 Analyst Ratings Have To Say About Arcellx
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023
Via Benzinga
Where Arcellx Stands With Analysts
Via Benzinga
Why Is Arcellx (ACLX) Stock Up 25% Today?
ACLX stock is usually under the radar, but today it's in the spotlight as Arcellx reveals a team-up with a well-known biotech business. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For February 13, 2023
Via Benzinga
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
From Gilead Sciences, Inc. and Arcellx, Inc.
Via Business Wire
20 Favorite Biotech & Medical Stocks For 2023
The way these stocks are setting up, many of them look great and will be at the forefront this coming year. 
Via Talk Markets
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
Dow Tumbles 100 Points; Silver Rises Over 2%
U.S. stocks traded mostly lower toward the end of trading with the Dow Jones dropping 100 points on Friday 
Via Benzinga
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session
Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate. 
Via Benzinga
US Stocks Turn Higher; Nasdaq Rises 40 Points
U.S. stocks traded slightly midway through trading with the Nasdaq gaining over 40 points on Friday 
Via Benzinga
Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences
The company inked a deal worth $325 million and up to $3.9 billion in milestones. 
Via Investor's Business Daily
US Stocks Edge Lower; Producer Prices Increase Higher Than Expected
U.S. stocks traded slightly lower this morning following the release of PPI data 
Via Benzinga
Gilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate
Via Benzinga
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
From Gilead Sciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
Upgrades 
Via Benzinga
Analyst Sees Market Potential For Arcellx Multiple Myeloma Candidate, Sees 50% Upside In Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 27, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
Upgrades 
Via Benzinga
More Than $6 Million Bet On JELD-WEN Holding? 3 Stocks Insiders are Buying
Although the US stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
63 Biggest Movers From Yesterday
Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Thursday after the company announced it received notification of euro 782.1 million of funding from the... 
Via Benzinga
Mid-Afternoon Market Update: Dow Dips 900 Points; AC Immune Shares Slide
U.S. stocks traded lower toward the end of trading, after the Federal Reserve raised fed funds rates by 0.75% to a new target range of between 1.5% and 1.75% on Wednesday. 
Via Benzinga
Mid-Day Market Update: Dow Tumbles 700 points; Advent Technologies Shares Spike Higher
U.S. stocks traded lower midway through trading, after the Federal Reserve raised fed funds rates by 0.75% to a new target range of between 1.5% and 1.75% on Wednesday. 
Via Benzinga
37 Stocks Moving In Thursday's Mid-Day Session
Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares jumped 153% to $2.94 after the company announced it received notification of euro 782.1 million of funding from the Greek State for the... 
Via Benzinga
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
82 Biggest Movers From Yesterday
Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.